Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to other OHAs). Group B: basal insulin alone or added to OHA mono/combination therapy. Group C: basal insulin plus rapid acting insulin combination therapy alone or added to OHA mono/combination therapy. P value was calculated by analysis of covariance with adjustment of baseline HbA1c.
